Monopar Therapeutics Inc. is a biopharmaceutical company. It is focused on developing drugs for cancer patients. The company's intellectual property pipeline consists of Validive(R), Camsirubicin (MNPR-201) and MNPR-101 which are in clinical stage. Monopar Therapeutics Inc. is based in Wilmette, United States.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-15.59M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.37 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -84.76% |
| Return on Assets (Trailing 12 Months) | -75.61% |
| Current Ratio (Most Recent Fiscal Quarter) | 11.48 |
| Quick Ratio (Most Recent Fiscal Quarter) | 11.48 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $9.02 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-2.23 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.11 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.60 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 6.12M |
| Free Float | 4.86M |
| Market Capitalization | $241.06M |
| Average Volume (Last 20 Days) | 0.02M |
| Beta (Past 60 Months) | 1.11 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 20.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 1.83% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |